Summary

The overall objective is to evaluate everolimus as an aldosterone-lowering drug in the treatment of primary hyperaldosteronism.

Study Name: Open-label Study on Treatment of Primary Aldosteronism With Everolimus
Status: Completed
Conditions: Primary aldosteronism
Interventions: Drug: Everolimus 0.75 mg
Locations: University Hospital Basel, Basel, Basel Stadt, Switzerland
Study link: https://ClinicalTrials.gov/show/NCT03174171

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.